We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy"

CONFIRM Cookie Policy

CONGRESSES

Our medical oncologists and laboratory investigators are regular speakers and organizers of some of the most important international seminars and scientific meetings.

We have presented the results of our investigations into the causes of cancer and novel treatments at some of the most important national and international oncology congresses.

BROWSE CONGRESSES
BY YEAR

Annual Meeting, American Society of Clinical Oncology (ASCO)

DATE02/06/2017 - 06/06/2017

PLACEChicago, USA

Alectinib vs. crizotinib  in ALK+ NSCLC (ALEX study)

Alice T. Shaw, Solange Peters, Tony Mok, Shirish M. Gadgeel, Jin Seok Ahn, Sai-Hong Ignatius Ou, Maurice Perol, Rafal Dziadziuszko, Dong-Wan Kim, Rafael Rosell, Ali Hassan Zeaiter, Ting Liu, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, D. Ross Camidge

Dacomitinib vs. gefitinib in EGFR mutant NSCLC (ARCHER 1050)

Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzanski, Rolf Linke, Eric Sbar, Tao Wang, Yi-Long Wu
[return] Phase 1/2 Study of Veliparib (V) Combined With Carboplatin (Cb) and Etoposide (E) in Patients (pts) With Extensive-stage Disease (ED) Small Cell Lung Cancer (SCLC) and Other Solid Tumors: Phase 1 Results
Florence Atrafi, Harry J. M. Groen, Lauren A. Byers, Elena Garralda, Martijn P. Lolkema, Randeep S. Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, Nashat Y. Gabrail, Tina Waskiewicz, Beibei Hu, Tu Xu, Hao Xiong, Elizabeth Hoening, Philip Komarnitsky, Antonio Calles

Interferon-gamma, a marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients
Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowsky, Ana Gimenez-Capitan, Cristina Teixidó, Miguel Angel Molina, Santiago Viteri, Daniela Morales, María de los Llanos Gil, María González Cao, Salvador Martín Algarra, Elisabeth Pérez-Ruiz, Iván Márquez-Rodas, Delvys Rodriguez-Abreu, Remei Blanco, Teresa Puértolas, María Angeles Royo, Rafael Rosell

HIV as a model for understanding immuno-oncology

DATE09/05/2017

PLACEAuditorium, Dexeus University Hospital

The objective of this meeting is to bring together scientists who share a common interest in immunotherapy with the aim of fostering new interdisciplinary approaches and inspiring scientists and clinicians. The workshop will provide a space for professionals from different disciplines to interact and share experiences, learn about the latest research findings, develop novel hypotheses, and enhance insights into how to modulate the immune response.

Cologne Conference on Lung Cancer

DATE06/04/2017

PLACECologne, Germany

Resistance to next-generation EGFR-inhibitors: consequences for clinical trial design Rosell R, MD, PhD



Overcoming resistance to targeted drugs: the clinical perspective Rosell R, MD, PhD


American Association for Cancer Research (AACR)

DATE01/04/2017 - 05/04/2017

PLACEWashington, USA

Routine Testing for KRAS mutations in cfDNA from blood of advanced cancer patients Garzón M, Mayo C, Jordana Ariza N, Balada i Bel A, García B, Villatoro S, Bertrán Alamillo J, Martínez Bueno A, Viteri Ramirez S, Pérez Rosado A, Morales Espinosa D, José Catalán M, Karachaliou N, Molina Vila M.A, Rosell R.



 


[return]

Analysis of EML4-ALK fusion transcripts in plasma and platelets to monitor response to crizotinib in EML4-ALK positive non-small cell lung cancer patients Aguado C, Teixidó C, Giménez-Capitán A, de los Llanos Gil M, Rodríguez S, Karachaliou N, Viteri S, Peg V, Aldeguer E, Alonso L, Rosell R, Molina-Vila M.A

Tumor cells with acquired resistance to EGFR inhibitors and overexpression or activation of AXL, MET and FGFR1 are insensitive to single-agent treatment targeting AXL, MET or FGFR Bertran-Alamillo J, Molina-Vila M.A, Teixidó C, Codony-Servat J, Giménez-Capitán J, Codony-Servat C, García-Román S, Aldeguer E, Rodríguez S, Rosell R

MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC)  are not associated with MET amplification and overexpression Giménez-Capitán A, Teixidó C, Rodríguez S, Aguado C, Bertran-Alamillo J, Castellví J, Yeste Z, Perez A, Rosell R, Molina-Vila M.A

Novel, non-invasive tools for lung cancer assessment

DATE20/03/2017 - 23/03/2017

PLACEDr. Rosell Oncology Institute

Course on the applications of exhaled breath condensate for lung cancer diagnostics given by Professor Giovanna Elisiana Carpagnano from the University of Foggia, Italy.